

## Literatur zum Artikel

## Biotechnologie und Krebs – Teil 1: Genomik und microRNA

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics 2013. *CA Cancer J Clin* 63: 11–30
2. Saedi B, Razmpa E, Sadeghi M, et al (2009) The epidemiology of laryngeal cancer in a country on the esophageal cancer belt. *Indian J Otolaryngol Head Neck Surg* 61: 213–217
3. Tran GD, Sun XD, Abnet CC, et al (2005) Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. *Int J Cancer* 113: 456–463
4. Brücher BL, Kitajima M, Siewert JR (2014) Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. *Cancer Invest* 32: 497–506
5. Liu SZ, Wang B, Zhang F, et al (2013) Incidence, survival and prevalence of esophageal and gastric cancer in Linzhou City from 2003 to 2009. *Asian Pac J Cancer Prev* 14: 6031–6034
6. Jemal A, Murray T, Ward E, et al (2005) Cancer statistics, 2005. *CA Cancer J Clin* 55: 10–30
7. Solaymani-Dodaran M, Card TR, West J (2013) Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study. *Gastroenterology* 144: 1375–1383
8. Lee JH, Kim KM, Cheong JH, et al (2012) Current management and future strategies of gastric cancer. *Yonsei Med J* 53: 248–257
9. Marshall BJ (1985) The pathogenesis of non-ulcer dyspepsia. *Med J Aust* 143: 319
10. Pisani P, Parkin DM, Muñoz N, et al (1997) Cancer and infection: estimates of the attributable fraction in 1990. *Cancer Epidemiol Biomarkers Prev* 6: 387–400
11. Conlin VS, Curtis SB, Zhao Y, et al (2004) *Helicobacter pylori* infection targets adherens junction regulatory proteins and results in increased rates of migration in human gastric epithelial cells. *Infect Immun* 72: 5181–5192
12. Dorward DW, Garon CF (1989) DNA-binding proteins in cells and membrane blebs of *Neisseria gonorrhoeae*. *J Bacteriol* 171: 4196–4201
13. Aravindan N, Aravindan S, Pandian V, et al (2014) Acquired tumor cell radiation resistance at the treatment site is mediated through radiation-orchestrated intercellular communication. *Int J Radiat Oncol Biol Phys* 88: 677–685
14. Brücher BLD, Jamall IS (2014) Epistemology of the origin of cancer: a new paradigm. *BMC Cancer* 14: 331
15. Brücher BLD, Jamall IS (2014) Cell-cell communication in tumor microenvironment, carcinogenesis and anticancer treatment. *Cell Physiol Biochem* 34: 213–243
16. Zhang Y, Pan KF, Zhang L, et al (2015) *Helicobacter pylori*, cyclooxygenase-2 and evolution of gastric lesions: results from an intervention trial in China. *Carcinogenesis* 36: 1572–1579
17. Blattner WA (1999) Human retroviruses: their role in cancer. *Proc Assoc Am Physicians* 111: 563–572
18. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 118: 3030–3044
19. Tomlinson IP, Novelli MR, Bodmer WF (1996) The mutation rate and cancer. *Proc Natl Acad Sci USA* 93: 14800–14803
20. Brücher BLD, Lyman G, van Hillegersberg R, et al (2014) Imagine a world without cancer. *BMC Cancer* 14: 186
21. Balogh LP (2015) Caging cancer. *Nanomedicine* 11: 867–869
22. Kleppe K, Ohtsuka E, Kleppe R, et al (1971) Studies on polynucleotides. XCVI. Repair replications of short synthetic DNA's as catalyzed by DNA polymerases. *J Mol Biol* 56: 341–361
23. Mullis K, Faloona F, Scharf S, et al (1986) Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. *Cold Spring Harb Symp Quant Biol* 51: 263–273
24. Saiki RK, Gelfand DH, Stoffel S, et al (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* 239: 487–491
25. Bernard PS, Wittwer CT (2002) Real-time PCR technology for cancer diagnostics. *Clin Chem* 48: 1178–1185
26. Kurimoto K, Yabuta Y, Ohinata Y, et al (2006) An improved single-cell cDNA amplification method for efficient high-density oligonucleotide microarray analysis. *Nucleic Acids Res* 34: e42
27. Bustin SA (2002) Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. *J Mol Endocrinol* 29: 23–39
28. Huggett J, Dheda K, Bustin S, et al (2005) Real-time RT-PCR normalisation; strategies and considerations. *Genes Immun* 6: 279–284
29. Vogelstein B, Papadopoulos N, Velculescu VE, et al (2013) Cancer genome landscapes. *Science* 339: 1546–1558
30. Tomasetti CB, Vogelstein B, Parmigiani G (2013) Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. *Proc Natl Acad Sci USA* 110: 1999–2004
31. Martin-Lorenzo A, Hauer J, Vicente-Duenas C, et al (2015) Infection exposure is a causal factor in B-precursor acute lymphoblastic leukemia as a result of Pax5 inherited susceptibility. *Cancer Discov* 5: 1328–1343
32. Nguyen LV, Makarem M, Carles A, et al (2014) Clonal analysis via barcoding reveals diverse growth and differentiation of transplanted mouse and human mammary stem cells. *Cell Stem Cell* 14: 253–263
33. Harris R, Law E, Sieuwerts A, et al (2015) Tamoxifen resistance driven by the DNA cytosine deaminase APOBEC3B in recurrent estrogen receptor positive breast cancer. *San Antonio Breast Cancer Symposium (SABC)*; Abstract S4–07
34. Ling S, Hu Z, Yang Z, et al (2015) Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution. *Proc Natl Acad Sci USA* 112: E6496–E6505
35. Vu V, Verster AJ, Schertzberg M, et al (2015) Natural variation in gene expression modulates the severity of mutant phenotypes. *Cell* 162: 391–402
36. Cvijovic I, Good BH, Jerison ER, et al (2015) Fate of a mutation in a fluctuating environment. *Proc Natl Acad Sci USA* 112: E5021–E5028
37. Supek F, Lehner B (2015) Differential DNA mismatch repair underlies mutation rate variation across the human genome. *Nature* 521: 81–84
38. Holstege H, Pfeiffer W, Sie D (2014) Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. *Genome Res* 24: 733–742
39. Lawrence MS, Stojanov P, Mermel CH, et al (2014) Discovery and saturation analysis of cancer genes across 21 tumor types. *Nature* 505: 495–501
40. Rosenfeld S (2013) Are the somatic mutation and tissue organization field theories of carcinogenesis incompatible? *Cancer Inform* 12: 221–229
41. Versteeg R (2014) Cancer: tumours outside the mutation box. *Nature* 506: 438–439
42. Mack SC, Witt H, Piro RM, et al (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. *Nature* 506: 445–450
43. Parker M, Mohankumar KM, PUNCHIHEWA C, et al (2014) C11orf95-RELA fusions drive oncogenic NF- $\kappa$ B signalling in ependymoma. *Nature* 506: 451–455
44. Huang CP, Cheng CM, Su HL, et al (2015) Syndecan-4 promotes epithelial tumor cells spreading and regulates the turnover of PKC $\alpha$  activity under mechanical stimulation on the elastomeric substrates. *Cell Physiol Biochem* 36: 1291–1304
45. Beerewinkel N, Antal T, Dingli D, et al (2007) Genetic progression and the waiting time to cancer. *PLoS Comput Biol* 3: e225
46. Tuch BB, Laborde RR, Xu X, et al (2010) Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. *PLoS One* 5: e9317
47. Pflueger D, Terry S, Sboner A, et al (2011) Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. *Genome Res* 21: 56–67
48. Ma S, Bao JY, Kwan PS, et al (2012) Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. *Gastroenterology* 143: 675–686, e1–12
49. Maher CA, Kumar-Sinha C, Cao X, et al (2009) Transcriptome sequencing to detect gene fusions in cancer. *Nature* 458: 97–101

50. Hu X, MacDonald DM, Huettnner PC, et al (2009) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. *Gynecol Oncol* 114: 457–464
51. Lee RC, Feinbaum RL, Ambros V (1993) The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell* 75: 843–854
52. Kumar MS, Lu J, Mercer KL, et al (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. *Nat Genet* 39: 673–677
53. Bentwich I, Avniel A, Karov Y, et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. *Nat Genet* 37: 766–770
54. Volinia S, Calin GA, Liu CG, et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 103: 2257–2261
55. Budhu A, Jia HL, Forgues M, et al (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. *Hepatology* 47: 897–907
56. Zhao Y, Jia HL, Zhou HJ, et al (2009) Identification of metastasis-related microRNAs of hepatocellular carcinoma in hepatocellular carcinoma cell lines by quantitative real time PCR. *Zhonghua Gan Zang Bing Za Zhi* 17: 526–530
57. Lee EJ, Gusev Y, Jiang J, et al (2007) Expression profiling identifies microRNA signature in pancreatic cancer. *Int J Cancer* 120: 1046–1054
58. Cheng H, Shi S, Cai X, et al (2012) microRNA signature for human pancreatic cancer invasion and metastasis. *Exp Ther Med* 4: 181–187
59. Brendle A, Lei H, Brandt A, et al (2008) Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. *Carcinogenesis* 29: 1394–1399
60. Sung H, Jeon S, Lee KM, et al (2012) Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival. *BMC Cancer* 12: 195
61. He H, Jazdzewski K, Li W, et al (2005) The role of microRNA genes in papillary thyroid carcinoma. *Proc Natl Acad Sci USA* 102: 19075–19080
62. Calin GA, Pekarsky Y, Croce CM (2007) The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. *Best Pract Res Clin Haematol* 20: 425–437
63. Feber A, Xi L, Luketich JD, et al (2008) MicroRNA expression profiles of esophageal cancer. *J Thorac Cardiovasc Surg* 135: 255–260
64. Mishima T, Akagi I, Miyashita M, et al (2009) Study of MicroRNA expression profiles of esophageal cancer. *J Nippon Med Sch* 76: 43
65. Hu Y, Correa AM, Hoque A, et al (2011) Prognostic significance of differentially expressed miRNAs in esophageal cancer. *Int J Cancer* 128: 132–143
66. Shinozuka E, Miyashita M, Mizuguchi Y, et al (2013) SnoN/SKIL modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells. *Biochem Biophys Res Commun* 430: 101–106
67. Mathé EA, Nguyen GH, Bowman ED, et al (2009) MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. *Clin Cancer Res* 215: 6192–6200
68. Hiyoshi Y, Kamohara H, Karashima R, et al (2009) MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. *Clin Cancer Res* 15: 1915–1922.
69. Guo Y, Chen Z, Zhang L, et al (2008) Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. *Cancer Res* 68: 26–33
70. Mori Y, Ishiguro H, Kuwabara Y, et al (2009) MicroRNA-21 induces cell proliferation and invasion in esophageal squamous cell carcinoma. *Mol Med Rep* 2: 235–239
71. Tjalsma H, Bolhuis A, Jongbloed JD, et al (2000) Signal peptide-dependent protein transport in *Bacillus subtilis*: a genome-based survey of the secretome. *Microbiol Mol Biol Rev* 64: 515–547
72. Agrawal GK, Jwa NS, Lebrun MH, et al (2010) Plant secretome: unlocking secrets of the secreted proteins. *Proteomics* 10: 799–827
73. Komatsu S, Ichikawa D, Takeshita H, et al (2011) Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. *Br J Cancer* 105: 104–111
74. Kurashige J, Kamohara H, Watanabe M, et al (2012) Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. *J Surg Oncol* 106: 188–192
75. Yu Y, Kanwar SS, Patel BB, et al (2012) MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. *Carcinogenesis* 33: 68–76
76. Ng R, Song G, Roll GR, et al (2012) A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. *J Clin Invest* 122: 1097–1108
77. Wang XC, Zhang ZB, Wang YY, et al (2013) Increased miRNA-22 expression sensitizes esophageal squamous cell carcinoma to irradiation. *J Radiat Res* 54: 401–408
78. Allawi HT, Dahlberg JE, Olson S, et al (2004) Quantitation of microRNAs using a modified Invader assay. *RNA* 10: 1153–1161
79. Neely LA, Patel S, Garver J, et al (2006) A single-molecule method for the quantitation of microRNA gene expression. *Nat Methods* 3: 41–46
80. Fassan M, Volinia S, Palatini J, et al (2011) MicroRNA expression profiling in human Barrett's carcinogenesis. *Int J Cancer* 129: 1661–1670
81. Nelson PT, Baldwin DA, Kloosterman WP, et al (2006) RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. *RNA* 12: 187–191
82. Li J, Li X, Li Y, et al (2013) Cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. *PLoS One* 8: e53582
83. Brennecke J, Stark A, Russell RB, et al (2005) Principles of microRNA-target recognition. *PLoS Biol* 3: e85
84. Krek A, Grün D, Poy MN, et al (2005) Combinatorial microRNA target predictions. *Nat Genet* 37: 495–500
85. Brodersen P, Voinnet O (2009) Revisiting the principles of microRNA target recognition and mode of action. *Nat Rev Mol Cell Biol* 10: 141–148
86. Scott GK, Mattie MD, Berger CE, et al (2006) Rapid alteration of microRNA levels by histone deacetylase inhibition. *Cancer Res* 66: 1277–1281
87. Da Cunha AB (1949) Genetic analysis of the polymorphism of color pattern in *Drosophila* polymorphia. *Evolution* 3: 239–251
88. National Center for Biotechnology Information, United States National Library of Medicine (2013) NCBI dbSNP build 138 for human: <http://www.ncbi.nlm.nih.gov/mailman/pipermail/dbsnp-announce/2013q3/000133.html>
89. Xue Y, Wang Q, Long Q, et al (2009) Human Y chromosome base-substitution mutation rate measured by direct sequencing in a deep-rooting pedigree. *Curr Biol* 19: 1453–1457
90. Human Genome Project (2013) [http://web.ornl.gov/sci/techresources/Human\\_Genome/project/info.shtml](http://web.ornl.gov/sci/techresources/Human_Genome/project/info.shtml)
91. Ensemble database at the European Bioinformatics Institute (EBI) and Wellcome Trust Sanger (2013) [http://useast.ensembl.org/Homo\\_sapiens/Location/Chromosome?r=1](http://useast.ensembl.org/Homo_sapiens/Location/Chromosome?r=1)
92. Watson JD, Baker TA, Bell SP, et al (2004) *Molecular biology of the gene*; 5th ed. Pearson/Benjamin Cummings San Francisco
93. Brouha B (2003) Hot L1s account for the bulk of retrotransposition in the human population. *Proc Nat Acad Sci* 100: 5280–5285
94. Bennett EA, Keller H, Mills RE, et al (2008) Active Alu retrotransposons in the human genome. *Genome Res* 18: 1875–1883
95. Wicker T, Sabot F, Hua-Van A, et al (2007) A unified classification system for eukaryotic transposable elements. *Nature Rev Genetics* 8: 973–982
96. Ju YS, Tubio JM, Mifsud W, et al (2015) Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. *Genome Res* 25: 814–824
97. Projectmanagement (2013) Requirements management for big data projects. <http://www.projectmanagement.com/articles/279834/Requirements-Management-for-Big-Data-Projects>
98. Dupont C, Armant DR, Brenner CA (2009) Epigenetics: definition, mechanisms and clinical perspective. *Semin Reprod Med* 27: 351–357
99. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med* 349: 2042–2054
100. Nie K, Zhang T, Allawi H, et al (2010) Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. *Am J Pathol* 177: 1470–1479
101. Kaz AM, Grady WM (2012) Epigenetic biomarkers in esophageal cancer. *Cancer Lett* 342: 193–199
102. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. *Carcinogenesis* 31: 27–36.
103. Eads CA, Lord RV, Wickramasinghe K, et al (2001) Epigenetic patterns in the progression of esophageal adenocarcinoma. *Cancer Res* 61: 3410–3418

104. Hibi K, Taguchi M, Nakayama H, et al (2001) Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. *Clin Cancer Res* 7: 3135–3138
105. Meng Y, Wang QG, Wang JX, et al (2011) Epigenetic inactivation of the SFRP1 gene in esophageal squamous cell carcinoma. *Dig Dis Sci* 56: 3195–3203
106. Meng XY, Zhu ST, Zong Y, et al (2011) Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma. *Dis Esophagus* 24: 444–449
107. Tong M, Chan KW, Bao JY, et al (2012) Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma. *Cancer Res* 72: 6024–6035
108. Xie L, Bourne PE (2015) Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem. *Front Pharmacol* 6: 1–5
109. Banki F, Mason RJ, Oh D, et al (2007) Plasma DNA as a molecular marker for completeness of resection and recurrent disease in patients with esophageal cancer. *Arch Surg* 142: 533–538
110. Hauser S, Kogej M, Fechner G, et al (2012) Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study. *Anticancer Res* 32: 3119–3124
111. Martini M, Vecchione L, Siena S, et al (2011) Targeted therapies: how personal should we go? *Nat Rev Clin Oncol* 9: 87–97
112. Heng HH, Stevens JB, Bremer SW, et al (2011) Evolutionary mechanisms and diversity in cancer. *Adv Cancer Res* 112: 217–253
113. Stepanenko AA, Vassetzky YS, Kavsan VM (2013) Antagonistic functional duality of cancer genes. *Gene* 529: 199–207
114. Qi Y, Chiu JF, Wang L, et al (2005) Comparative proteomic analysis of esophageal squamous cell carcinoma. *Proteomics* 5: 2960–2971
115. Jazii FR, Najafi Z, Malekzadeh R, et al (2006) Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. *World J Gastroenterol* 12: 7104–7112
116. Schaaij-Visser TB, Graveland AP, Gauci S, et al (2009) Differential proteomics identifies protein biomarkers that predict local relapse of head and neck squamous cell carcinomas. *Clin Cancer Res* 15: 7666–7675
117. Wang LD, Wang DC, Zheng S, et al (2006) Serum proteomic profiles of the subjects with esophageal precancerous and cancerous lesions from Linzhou, an area with high incidence of esophageal cancer in Henan Province, Northern China. *Ai Zheng* 25: 549–554
118. Gourin CG, Zhi W, Adam BL (2009) Proteomic identification of serum biomarkers for head and neck cancer surveillance. *Laryngoscope* 119: 1291–1302
119. Voskuil J (2015) How difficult is the validation of clinical biomarkers? *F1000Res* 4: 101
120. Ferreira R, Oliveira P, Martins T, et al (2015) Comparative proteomic analyses of urine from rat urothelial carcinoma chemically induced by exposure to N-butyl-N-(4-hydroxybutyl)-nitrosamine. *Mol Biosyst* 11: 11594–11602
121. Ha GH, Lee SU, Kang DG, et al (2002) Proteome analysis of human stomach tissue: separation of soluble proteins by two-dimensional polyacrylamide gel electrophoresis and identification by mass spectrometry. *Electrophoresis* 23: 2513–2524
122. Paulo JA, Lee LS, Wu B, et al (2010) Proteomic analysis of endoscopically (endoscopic pancreatic function test) collected gastroduodenal fluid using in-gel tryptic digestion followed by LC-MS/MS. *Proteomics Clin Appl* 4: 715–725
123. Chung JY, Braunschweig T, Hu N, et al (2006) A multiplex tissue immunoblotting assay for proteomic profiling: a pilot study of the normal to tumor transition of esophageal squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 15: 1403–1408
124. Du XL, Hu H, Lin DC, et al (2007) Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. *J Mol Med (Berl)* 85: 863–875
125. Kashyap MK, Harsha HC, Renuse S, et al (2010) SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. *Cancer Biol Ther* 10: 796–810
126. Uemura N, Nakanishi Y, Kato H, et al (2009) Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. *Int J Cancer* 124: 2106–2115
127. Uemura N, Nakanishi Y, Kato H, et al (2009) Antibody-based proteomics for esophageal cancer: identification of proteins in the nuclear factor-kappaB pathway and mitotic checkpoint. *Cancer Sci* 100: 1612–1622
128. Fu L, Qin YR, Xie D, et al (2007) Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. *Cancer* 110: 2672–2681
129. Hu H, Ran Y, Zhang Y, et al (2009) Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target. *Mol Cell Proteomics* 8: 816–826
130. Xie LX, Zhai TT, Yang LP, et al (2013) Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-oesophageal junction adenocarcinoma. *Int J Exp Pathol* 94: 39–46
131. Moghanibashi M, Jazii FR, Soheili ZS, et al (2012) Proteomics of a new esophageal cancer cell line established from Persian patient. *Gene* 500: 124–133
132. Moghanibashi M, Rastgar Jazii F, Soheili ZS, et al (2013) Esophageal cancer alters the expression of nuclear pore complex binding protein Hsc70 and eIF5A-1. *Funct Integr Genomics* 13: 253–260
133. Qi YJ, He QY, Ma YF, et al (2008) Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma. *J Cell Biochem* 104: 1625–1635
134. Cohen M, Yossef R, Erez T, et al (2011) Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. *PLoS One* 6(1): e14540
135. Juan HF, Chen JH, Hsu WT, et al (2004) Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. *Proteomics* 4: 2766–2775
136. Metzger R, Bollschweiler E, Hölscher AH, et al (2010) ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. *Future Oncol* 6: 1735–1749
137. Nishimori T, Tomonaga T, Matsushita K, et al (2006) Proteomic analysis of primary esophageal squamous cell carcinoma reveals downregulation of a cell adhesion protein, periplakin. *Proteomics* 6: 1011–1018
138. Zhang LY, Ying WT, Mao YS, et al (2003) Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. *World J Gastroenterol* 9: 650–654
139. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. *Mol Cell Proteomics* 1: 845–867
140. Hortin GL, Sviridov D, Anderson NL (2008) High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. *Clin Chem* 54: 1608–1616
141. Wang P, Whiteaker JR, Paulovich AG (2009) The evolving role of mass spectrometry in cancer biomarker discovery. *Cancer Biol Ther* 8: 1083–1094
142. Omenn GS, States DJ, Adamski M, et al (2005) Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. *Proteomics* 5: 3226–3245
143. Haab BB, Geierstanger BH, Michailidis G, et al (2005) Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. *Proteomics* 5: 3278–3291
144. Rai AJ, Gelfand CA, Haywood BC, et al (2005) HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. *Proteomics* 5: 3262–3277
145. Neimark J (2014) The dirty little secret in cancer research. 2nd Oct: <http://discovermagazine.com/2014/nov/20-trial-and-error>
146. Gey GO, Coffman WD, Kubicek MT (1952) Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. *Cancer Res* 12: 264–265
147. Jenkin HM, Hung SC (1967) Effect of vancomycin on the growth of psittacosis-chromia agents cultivated in eggs and cell culture. *Appl Microbiol* 15: 10–12
148. Dirks WG1, Drexler HG (2011) Online verification of human cell line identity by STR DNA typing. *Methods Mol Biol* 731: 45–55
149. Ando T, Ishiguro H, Kuwabara Y, et al (2008) Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. *Dis Esophagus* 21: 15–20
150. Domcke S, Sinha R, Levine DA, et al (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. *Nat Commun* 4: 1–10
151. Van Noorden R (2015) Interdisciplinary research by the numbers. *Nature* 525: 306–307
152. Begley CG, Ellis LM (2012) Drug development: Raise standards for preclinical cancer research. *Nature* 483: 531–533